Page 2 of 2
Results 76 - 109 of 109
No image set
Etranacogene Dezaparvovec, an Enhanced Vector for Gene Transfer in Adults (Drygalski)
No image set
Efficacy and Safety of Etranacogene Dezaparvovec in Adults
No image set
Thrombotic Thrombocytopenic Purpura (TTP) Podcasts
No image set
Cancer-Associated Thrombosis: Catheter-related Thrombosis (CRT) VTE
No image set
Approach to the Patient With Cancer-associated VTE
No image set
Cancer-Associated Thrombosis: Primary Prophylaxis
No image set
Understanding and Recognizing TTP
No image set
How to Treat iTTP in 2020
No image set
TTP: Complexities and Comorbidities
No image set
Monitoring of Immnune Mediated TTP
No image set
Diagnosis of TTP
No image set
Key Considerations: Advances in Gene Therapy for Hemophilia
No image set
Integrating Emerging Treatments for Hemophilia A
No image set
Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Vector Gene Transfer
No image set
Gene Therapy for Treatment of Hemophilia: Other Strategies and Targets
9915-conf_covg_icon_263x149
Conference Coverage from ISTH 2019 in Melbourne
9915-mod3-icon
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
No image set
Gene Therapy for Treatment of Hemophilia: Common Concerns in Gene Therapy
9915-mod2-icon
A History of Hemophilia Treatment: Factor Replacement to Gene Therapy
9915-mod1-icon
Getting to Know Gene Therapy: Terminology and Concepts
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
Page 2 of 2

Search